01485nas a2200457   4500000000100000000000100001008004100002653003100043653002800074653004000102653002600142653002200168653003000190653001100220653004000231653002800271653003000299653002400329653008600353653002600439653000900465653003200474653002800506653002500534653004200559653002300601100001500624700001300639700001300652700001200665700001500677700001200692700001500704700001400719700001500733245021200748250001500960300001400975490000700989020003100996       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones10aAdrenergic beta-2 Receptor Agonists10aBronchodilator Agents10aDrug Combinations10aDrug Therapy, Combination10aHumans10aMuscarinic Agonists/therapeutic use10a*Muscarinic Antagonists10aNebulizers and Vaporizers10aPrimary health care10a*Pulmonary Disease, Chronic Obstructive/chemically induced/diagnosis/drug therapy10aRetrospective Studies10aCopd10ainitial maintenance therapy10apatient characteristics10aprimary care setting10asingle-inhaler LAMA/LABA dual therapy10atreatment patterns1 aG. Requena1 aV. Banks1 aA. Czira1 aR. Wood1 aT. Tritton1 aR. Wild1 aC. Compton1 aM. Duarte1 aA. Ismaila00aCharacterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England  a2022/08/20  a1781-17950 v17  a1176-9106 (Print)1176-9106